60results about "Mammal lectins" patented technology

The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use for prevention, treatment and cure of inflammation due to chemotherapy and / or radiotherapy. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 70% homology to SEQ ID NO: 1.

The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:1, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purification of recombinant lectin having amino acid sequence of SEQ ID NO: 1.

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

Certain aspects of the present disclosure relate to industrial scale production and recovery of lectin proteins. Certain aspects relate to recombinant gram-positive bacterial cells that produce heterologous lectin proteins. Certain other aspects relate to compositions and methods for recovering and / or purifying one or more lectins and lectin formulations with improved purity thereof.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

A high-mannose antibody-specific affinity material, a preparation method therefor and a use thereof. Provided are a lectin variant comprising (a) a histidine tag and (b) a cysteine-containing segment, added to the C-terminus of a reference lectin; a nucleic acid molecule encoding the lectin variant, and a vector and a cell containing the nucleic acid molecule; a composition and a matrix comprising the lectin variant; and a use of the lectin variant for reducing or removing a high-mannose antibody from a sample. The lectin variant has a specific affinity for high-mannose antibodies, and can effectively bind to high-mannose antibodies formed during antibody production, to remove high-mannose byproducts contained in recombinant antibodies, thereby effectively promoting and achieving required antibody purification in downstream stages of production.

The present invention relates to a recombinant stabilized galectin 9 protein and the use thereof, and more specifically, relates to a pharmaceutical composition comprising the recombinant stabilized galectin 9 protein for prevention or treatment of rheumatoid arthritis and a bone disease. The recombinant stabilized galectin 9 protein differs from the wild-type galectin 9 protein in that the amino acids in the link region connecting two carbohydrates recognition domains (CRDs) are deleted, and the amino acids in the C-terminal CRD (CCRD) are deleted and substituted.

Certain aspects of the instant disclosure are related to the industrial scale production and recovery of lectin proteins. Certain aspects are related to recombinant Gram-positive bacterial cells producing heterologous lectin proteins. Certain other aspects are related to compositions and methods for recovering and / or purifying one or more lectins and enhanced purity lectin preparations thereof.

The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

To develop methods or compositions for normalizing or promoting the maturation of the vasculature in diseases (such as cancer).SOLUTION: The present application provides agents that specifically inhibit the IGFBP7 / CD93 signaling pathway, such as agents that specifically block the interaction between CD93 and IGFBP7, methods of using the agents and methods of identifying the agents.SELECTED DRAWING: None

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1.

The present disclosure provides trefoil factor 2 / interferon α2 fusion proteins and their use in the prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides fusion proteins that contain a trefoil factor 2 (TFF2) element that includes a TFF2 peptide, and an interferon α2 (IFNα2) element that includes an IFNα2 peptide fused to the TFF2 element. The present disclosure also provides uses of such fusion proteins in the prevention and / or treatment of viral infectious diseases, such as acute respiratory / enteric viral infections.

This disclosure contemplates recombinant oligomannose binding lectins reported herein. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for purification and detection methods. In certain embodiments, this disclosure contemplates uses of recombinant oligomannose binding lectins disclosed herein for treating or preventing viral infections, cancer, or other immunological diseases or conditions. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising recombinant oligomannose binding lectins disclosed herein or nucleic acid or vector encoding the same.

The invention provides compositions and methods for treating, reducing or preventing cytokine storm, for example, in connection with a viral infection (e.g., by SARS-CoV-2), drug treatment or therapy, trauma or an inflammatory disease, or a related disease and disorder.

The present invention is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The present invention relates to a novel SPD-TNFSF fusion protein comprising a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein comprising a plurality of SPD-TNFSF fusion proteins. The present invention also provides an expression vector as mRNA, plasmid or virus comprising an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition comprising thereof.

A bifunctional peptide is provided, the bifunctional peptide comprising a virus binding moiety and a mucin binding moiety covalently bound to the virus binding moiety. The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and / or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.

The present invention relates to fusion proteins which interact with and regulate the activation and / or the activity of the complement system. Preferably the fusion protein comprises a pattern recognition molecule (PRM) or a fragment thereof and a complement control protein (CCP) or a fragment thereof.

The present disclosure provides a chimeric antigen receptor (CAR) for human C-type lectin-like molecule-1 (CLL-1) comprising a polypeptide, the chimeric antigen receptor comprising an extracellular antigen-binding domain comprising a single anti-CLL-1 heavy chain variable domain (VH) and a single anti-CLL-1 light chain variable domain (VL), a transmembrane domain, and an intracellular signaling domain. Also disclosed are immune effector cells and immune effector cell-based pharmaceutical compositions comprising the CAR, as well as therapeutic uses thereof in the treatment of diseases associated with CLL-1.

The present disclosure provides a T-cell modulatory multimeric polypeptide (TMMP) comprising at least one heterodimer, where the heterodimer comprises first and second polypeptide chains and where the heterodimer includes an NKG2 peptide, an HLA-E heavy chain polypeptide, a beta-2 microglobulin polypeptide, and an immunoglobulin Fc polypeptide. The heterodimer can also include an immunomodulatory polypeptide and / or a cancer-targeting polypeptide. The TMMPs are useful in methods of modulating an immune response, which methods are also provided.

Described herein are Galectin-1 / Galectin-3 multivalent protein complexes and uses thereof. In some aspects, Galectin-1 / Galectin-3 multivalent protein complexes are useful to treat inflammatory conditions in a subject.

Provided herein are chimeric antigen receptors (CARs) that include a) an antigen binding domain specific for an antigen, b) a spacer, c) a transmembrane domain, and d) an intracellular signaling domain, wherein the spacer consists of 1, 2 or 3 C2-set Ig-like domain(s) e.g., C2-set Ig-like domains of the sialic acid binding Ig-like lectin (Siglec) family. Also provided herein are compositions including a) an immune cell expressing a CAR, wherein the CAR is specific for a tag and b) a tagged polypeptide.

Provided is a fusion construct that includes (1) a glycan-targeting domain capable of specifically binding a pre-determined sugar molecule (such as one over-expressed on certain cancer cell surface), (2) an aggregating domain capable of self-aggregation to form multimers among molecules containing the same domain, and (3) an optional solubilizing domain, which is connected to (1) or (2) via a peptide linker optionally containing a protease (such as one over-expressed on certain cancer cell surface) cleavage site. Also provided is using of said construct in treatment of cancer.

The present invention relates to a process for preparing a recombinant lectin having the amino acid sequence of SEQ ID NO: 1, wherein the process comprises fed-batch fermentation of a clone in a host cell at a carbon to nitrogen ratio of 3:1 to 6:1 and at a specific feed rate. The present invention also relates to a purification process for the recombinant lectin having the amino acid sequence of SEQ ID NO: 1.

Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.

The invention provides compositions and methods for treating, reducing or preventing cytokine storm, for example, in connection with a viral infection (e.g., by SARS-CoV-2), drug treatment or therapy, trauma or an inflammatory disease, or a related disease and disorder.

Provided herein, inter alia, are variant lectin anti-viral polypeptides as well as compositions and methods for expressing and using the same for the treatment and prevention of viral disease in animals.

The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use for prevention, treatment and cure of inflammation due to chemotherapy and / or radiotherapy. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 70% homology to SEQ ID NO: 1.